New gene therapy for chronic heart failure
Novel Gene Therapy For Chronic Ischemic Heart Failure
This study is testing a new gene therapy to help improve heart function in dogs with chronic heart failure, aiming to make their hearts pump better and reduce the chances of irregular heartbeats.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11011488 on NIH RePORTER |
What this research studies
This research focuses on developing a novel gene therapy aimed at treating chronic ischemic heart failure, a condition where the heart struggles to pump blood effectively. The approach involves using a canine model to test the effectiveness of cBIN1 gene therapy, which targets the heart muscle directly to improve calcium handling and restore heart function. By understanding how calcium microdomains are disrupted in heart failure, the researchers aim to develop a treatment that could significantly enhance heart performance and reduce the risk of arrhythmias.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with chronic ischemic heart failure who have not responded well to existing therapies.
Not a fit: Patients with heart failure due to non-ischemic causes or those who are not candidates for gene therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment for patients suffering from chronic heart failure, potentially improving their quality of life and survival rates.
How similar studies have performed: Previous research has shown promise in using gene therapy for heart failure in small animal models, but this approach is novel in large animal models and has yet to be tested in humans.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Shaw, Robin M — University of Utah
- Study coordinator: Shaw, Robin M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.